Loss of heterozygosity is detected at chromosomes 1p35-36 (NB), 3p25 (VHL), 16p13 (TSC2/PKD1), and 17p13 (TP53) in microdissected apocrine carcinomas of the breast

Modern Pathology

Volumn 12, Issue 12, 1999, Pages 1083-1089

  Lininger, Ruth A ^a   Zhuang, Zhengping ^c   Man, YanGao ^b   Park, Won Sang ^c   Emmert Buck, Michael ^c   Tavassoli, Fattaneh A ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Apocrine; Breast; Genetics; Neoplasms

Indexed keywords

APOCRINE CARCINOMA; ARTICLE; BREAST CARCINOMA; CHROMOSOME 16P; CHROMOSOME 17P; CHROMOSOME 1P; CHROMOSOME 3P; CLINICAL ARTICLE; CONTROLLED STUDY; GENE LOCUS; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ALLELES; APOCRINE GLANDS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 16; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 3; DNA, NEOPLASM; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; LOSS OF HETEROZYGOSITY; POLYMERASE CHAIN REACTION; SWEAT GLAND NEOPLASMS;

EID: 0033378094     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Tavassoli F, Norris H. Intraductal apocrine carcinoma. A clinicopathologic study of 37 cases. Mod Pathol 1994;7:813-8.
2. Tavassoli F. Pathology of the breast. New York; Appleton & Lange ; 1992.
3. Azzopardi J. Problems in breast pathology. Major problems in surgical pathology. London: W.B. Saunders; 1979.
4. Frable W, Kay S. Carcinoma of the breast: histologic and clinical features of apocrine tumors. Cancer 1968;21:756-63.
5. Mazoujian G, Bodian C, Haagensen D J, Haagensen C. Expression of GCDFP-15 in breast carcinomas. Relationship to pathologic and clinical factors. Cancer 1989;63:2156-61.
6. Haagensen DJ, Dilley W, Mozoujian G, Wells SJ. Review of GCDFP-15: an apocrine marker protein. Ann NY Acad Sci 1990;586:161-73.
7. Abati A, Kimmel M, Rosen P. Apocrine mammary carcinoma. A clinicopathologic study of 72 cases. Am J Clin Pathol 1990;94:371-7.
8. Fisher E, Agregorio R, Fisher B. The pathology of invasive breast carcinomas. Cancer 1975;36:1-78.
9. Rosen P. The pathological classification of mammary carcinoma: past, present, and future. Ann Clin Lab Sci 1979;9: 144-56.
10. Mossler J, Barton T, Brinkhous A, McCarty K, Moylan J, McCarty K Jr. Apocrine differentiation in human carcinoma. Cancer 1980;46:2463-71.
11. Tavassoli F, Purcell C, Bratthauer G, Man Y-G. Androgen receptor expression along with loss of bcl-2, ER, and PR expression in benign and malignant apocrine lesions of the breast: implications for therapy. Breast J 1996;2:261-9.
12. Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ. Androgen receptors in breast cancer. Cancer 1984; 54:2436-40.
13. Isola JJ. Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J Pathol 1993;170:31-5.
14. Kuenen-Boumeester V, van der Kwast TH, van Putten WLJ, Claassen C, van Ooijen B, Henzen-Logmans SC. Immunohistochemical determination of androgen receptors in relation to oestrogen and progesterone receptors in female breast cancer. Int J Cancer 1992;52:581-4.
15. Hall RE, Clements JA, Birrell SN, Tilley WD. Prostate-specific antigen and gross cystic disease fluid protein-15 are co-expressed in androgen receptor-positive breast tumours. Br J Cancer 1998;78:360-5.
16. Smith H, Lu Y, Deng G, Martinez O, Krams S, Ljung B-M, et al. Molecular aspects of early stages of breast cancer progression. J Cell Biochem 1993;17G:144-52.
17. Callahan R, Cropp CS, Merlo GR, Liscia DS, Cappa APM, Lidereau R. Somatic mutations and human breast cancer. Cancer 1992;69:1582-8.
18. Sato T, Tanigami A, Yamakawa K, Akiyama F, Kasumi F, Sakamoto G, et al. Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer. Cancer Res 1990;50:7184-9.
19. Lakhani S, Slack D, Hamoudi R, Collins N, Stratton M, Sloane J. Detection of allelic imbalance indicates that a proportion of mammary hyperplasia of usual type are clonal, neoplastic proliferations. Lab Invest 1996;74:129-35.
20. Lininger RA, Zhuang Z, Man YG, Pham T, Park WS, MacGrogan G, et al. LOH at p13 detected in microdissected papillary neoplasms of the breast and their precursors. Hum Pathol 1998;29:1113-8.
21. Tsuda H, Uei Y, Fukutomi T, Hirohashi S. Different incidence of loss of heterozygosity on chromosome 16q between intraductal papilloma and intracystic papillary carcinoma of the breast. Jpn J Cancer Res 1994;85:992-6.
22. Tsuda H, Callen D, Fukutomi T, Nakamura Y, Hirohashi S. Allele loss on chromosome 16q24.2-qter occurs frequently in breast cancers irrespectively of difference in phenotype and extent of spread. Cancer Res 1994;54:513-7.
23. Zhuang Z, Berttheau P, Emmert-Buck M, Liotta L, Gnarra J, Linehan W, et al. A new microdissection technique for archival DNA analysis of specific cell populations in lesions less than one millimeter. Am J Pathol 1995;146:620-5.
24. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
25. Tsuchida Y, Hemmi H, Inoue A, Obana K, Yang H, Hayashi Y, et al. Genetic clinical markers of human neuroblastoma with special reference to N-myc oncogene: amplified or not amplified? An overview. Tumour Biol 1996;17:65-74.
26. Brodeur G. Molecular basis for heterogeneity in human neuroblastomas. Eur J Cancer 1995;31A:505-10.
27. Munn K, Walker R, Varley J. Frequent alterations of chromosome 1 in ductal carcinoma in situ of the breast. Oncogene 1995;10:1653-7.
28. Nagai H, Negrini M, Carter S, Gillum D, Rosenberg A, Schwartz G, at al. Detection and cloning of a common region of loss of heterozygosity at chromosome 1p in breast cancer. Cancer Res 1995;55:1752-7.
29. Genuardi M, Tsihira H, Anderson D, Saunders G. Distal deletion of chromosome 1p in ductal carcinoma of the breast. Am J Hum Genet 1989;45:73-82.
30. Hoggard N, Brintnell B, Howell A, Weissenbach J, Varley J. Allelic imbalance on chromosome 1 in human breast cancer. II. Microsatellite repeat analysis. Genes Chromosomes Cancer 1995;12:24-31.
31. Seizinger B, Klinger H, Junien C, Nakamura Y, Le Beau M, Cavenee W, et al. V. Report of the committee on chromosome and gene loss in human neoplasia. Cytogenet Cell Genet 1991;58:1080-96.
32. Green A, Smith M, Yates J. Loss of heterozygosity on chromosome 16p13.3 in hamartomas from tuberous sclerosis patients. Nature Genet 1994;6:193-6.
33. Henske E, Neumann H, Scheithauer B, Herbst E, Short M, Kwiatkowski D. Loss of heterozygosity in the tuberous sclerosis (TSC2) region of chromosome band 16p13 occurs in sporadic as well as TSC-associated renal angiomyolipomas. Genes Chromosomes Cancer 1995;13:295-8.
34. Maher E, Webster A, Richards F, Green J, Crossey P, Payne S, et al. Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. J Med Genet 1996;33:328-32.
35. Kenck C, Wilhelm M, Bugert P, Staehler G, Kovacs G. Mutation of the VHL gene is associated exclusively with the development of non-papillary renal cell carcinomas. J Pathol 1996;179:157-61.
36. Zhuang Z, Emmert-Buck M, Roth M, Gnarra J, Linehan W, Liotta L, et al. von Hippel-Lindau disease gene deletion detected in microdissected sporadic human colon carcinoma specimens. Hum Pathol 1996;27:152-6.
37. Bailly M, Bain C, Favrot M-C, Ozturk M. Somatic mutations of von Hippel-Lindau (VHL) tumor-suppressor gene in European kidney cancers. Int J Cancer 1995;63:660-4.
38. Miller C, Aslo A, Campbell M, Kawamata N, Lampkin B, Koeffler H. Alterations of the p15, p16, and p18 genes in osteosarcoma. Cancer Genet Cytogenet 1996;86:136-42.
39. Kamb A, Gruis N, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian S, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-9.
40. Rush E, Abouezzi Z, Borgen P, Anelli A. Analysis of MTS1/CDK4 in female breast carcinomas. Cancer Lett 1995;89: 223-6.